A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

NCT03293992 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-angle
Ocular Hypertension

Interventions

DRUG: 0.01% RO7058584
DRUG: 0.1% RO7058584
DRUG: 1% RO7058584
DRUG: Matching Placebo
DRUG: Latanoprost 0.005%

Sponsor

Hoffmann-La Roche